PEP Health Unveils the First Real-Time Trust Score for U.S. Healthcare
MINNEAPOLIS, April 29, 2025 /PRNewswire/ - PEP Health, the AI-powered patient experience platform trusted by leading hospitals, payers, and health systems, today announced the launch of its Trust Score, the first real-time, validated metric that quantifies how patients experience and express trust in healthcare.
Built from millions of unsolicited patient narratives and developed alongside a leading U.S. health system, the Trust Score brings long-missing measurement, visibility, and actionability to one of the most critical drivers of health outcomes: patient trust.
Download PEP Health's Trust white paper here.
'In healthcare, trust isn't abstract. It directly impacts outcomes, adherence, and loyalty,' said Dr. Mark Lomax, CEO of PEP Health. 'For the first time, hospitals, payers, and providers can measure trust in real time, pinpoint when and where it erodes, and take immediate steps to rebuild it.'
The Trust Score is already being piloted nationwide, including at ECU Health, a rural health system committed to human-centered care.
'Trust is the foundation of the relationship between healthcare and those they serve. When trust is present in the relationship, patients adhere to treatment plans, seek medical care when needed, and have frank conversations with their care team which is vital to their health planning,' said Dr. Julie Kennedy Oehlert, Chief Experience Officer at ECU Health. 'This trust also fuels the passion and purpose of those that provide care, insulating against burnout.'
More Than a Feeling: Why Trust Now Has a Score
While traditional surveys often struggle with delays, low response rates, and limited reach, PEP Health's Trust Score draws from the real, unprompted voices of patients, capturing their experiences across social media platforms, review sites, and forums. Using advanced machine learning and healthcare-specific natural language processing (NLP) technology, PEP Health analyzes this data into structured insights that reflect the full spectrum of patient experience.
At the core of the Trust Score are Drivers of Trust (such as caring, kindness, effective listening) and Indicators of Trust (such as patient retention and health outcomes)
PEP Health's patient experience insights are validated against national benchmarks including HCAHPS and insurer quality metrics and highlighted in peer-reviewed research published in BMJ Quality & Safety and The Lancet (read more here ).
A Strategic Metric for Today's Healthcare Leaders
Trust is no longer just a value statement: it directly affects health equity, financial performance, and community engagement. Internal PEP Health data shows that a one-point decline in patient satisfaction can result in more than $12 million in annual lost revenue for a large health system.
With the Trust Score, healthcare leaders can now:
'For too long, others have defined what trust should look like in healthcare,' continued Dr. Lomax. 'It's time to listen to patients themselves. When trust breaks down, patients don't show up, don't open up, and don't follow through. Now, for the first time, we can measure trust and take meaningful action to rebuild it.'
Early Access and White Paper
Healthcare leaders can now download PEP Health's new white paper and apply for early access to the Trust Score platform by completing the Early Access request form.
About PEP Health
PEP Health's advanced AI uses healthcare-specific natural language processing (NLP) and machine learning to analyze diverse, unsolicited patient feedback from online sources such as social media, review platforms, and forums, alongside hospital surveys and internal data. By providing a comprehensive, real-time view of patient and community experiences, PEP Health helps healthcare providers gain insights that traditional surveys often miss. This approach enables organizations to understand patient preferences more deeply, focus on what matters most, and align care with evolving expectations.
To learn more, please visit www.pephealth.ai
View original content: https://www.prnewswire.com/news-releases/pep-health-unveils-the-first-real-time-trust-score-for-us-healthcare-302440219.html
SOURCE PEP Health
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 days ago
- Associated Press
DermRays Celebrates 13 Years of Skincare Innovation with Exclusive Anniversary Sale and Groundbreaking 1450nm Laser Device for 2026
PLEASANTON, Calif., Aug. 15, 2025 /PRNewswire/ -- DermRays, a pioneer in at-home skincare technology, marks its 13th anniversary with a celebration of its best-selling devices and a sneak peek at its upcoming 1450nm laser skincare tool, slated for launch in early 2026. This milestone underscores the brands commitment to merging cutting-edge science with accessible beauty solutions. Anniversary Spotlight: Award-Winning Skincare Heroes To thank customers for their trust, DermRays is offering limited-time discounts on three transformative devices designed to rejuvenate skin at home: 1. DermRays Revive The first and only at-home laser with ultra-high energy for collagen regeneration. Ideal for reducing fine lines and boosting collagen, its a clinic-grade tool for a fraction of the cost. Revive uses cutting-edge 1064nm laser technology, the same as that employed by leading salon brands. 2. FusionGlow Multi-Functional Microcurrent Toning Device Beyond Microcurrent: 5 Skincare Technologies You Need. Comprehensive Skin Revitalization: Brighten, Hydrate, Rejuvenate. Achieve radiant, firm skin in 14 days with clinically visible results backed by SGS. 3. LED Light Therapy Silicone Mask Your daily skincare companion: blue, red, infrared, and mixed light for every need. Only 15 minutes a day for youthful and radiant skin. 'For 13 years, we've empowered users to take control of their skincare routines with safe, effective technology,' says Dr. Yang Lin, Brand Director at DermRays. 'Our anniversary sale is a tribute to our community-and just the beginning of whats next.' 4. The Future: 1450nm Laser Skincare Device DermRays is set to revolutionize at-home treatments again with its 1450nm laser device (expected Q1 2026). It stimulates natural collagen production to smooth fine lines, restore firmness, and reverse signs of aging. This tool will expand the brands professional-grade offerings, bridging the gap between spa treatments and home care. Join the Celebration From August 1-31, 2025, enjoy exclusive anniversary bundles and discounts on DermRays bestselling devices. Follow @DermRays on social media for giveaways and live demos. About DermRays Since 2011, DermRays has combined dermatological research with accessible technology, offering FDA/CE/UKCA-cleared, non-invasive devices for radiant, youthful skin at home. View original content to download multimedia: SOURCE DermRays
Yahoo
2 days ago
- Yahoo
Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Epigenetics Market, valued at US$2.03 billion in 2024, stood at US$2.24 billion in 2025 and is projected to advance at a resilient CAGR of 13.9% from 2025 to 2030, culminating in a forecasted valuation of US$4.29 billion by the end of the period. The major factors driving the growth in the flow cytometry market include advancements in technology, increasing adoption of flow cytometry products in clinical diagnostics, rising prevalence of chronic diseases, growing biopharmaceutical R&D, and the need for precision medicine. The significant rise in oncology research has increased the demand for flow cytometry products and services. Additionally, the integration of AI and machine learning is enhancing data analysis capabilities, further fueling market growth. Download PDF Brochure: Browse in-depth TOC on "Epigenetics Market" 365 - Tables45 - Figures353 - Pages By offering, the global epigenetics market is segmented into various categories, including kits and reagents, enzymes, instruments and accessories, software, and services. Within the kits and reagents category, there are sub-segments such as antibodies, chip-sequencing kits and reagents, bisulfite conversion kits and reagents, whole-genome amplification kits and reagents, 5-HMC and 5-MC analysis kits and reagents, histones, as well as other kits and reagents. In 2024, the Antibodies segment is projected to command the largest market share. This is attributed to the increasing reliance on antibodies for the detection, identification, and modification of proteins, along with their essential function in monitoring cellular regulation and gene expression. Consequently, the growth of the antibodies segment is expected to accelerate throughout the forecast period due to these advancements. By Method, the epigenetics market segmentation by methodology includes DNA methylation, histone modifications, and additional approaches such as non-coding RNA interactions and chromatin remodeling. The DNA methylation segment is projected to exhibit a robust compound annual growth rate (CAGR) throughout the forecast period, primarily driven by its proven effectiveness in oncology research applications. By geography, The Asia Pacific region is projected to experience the most rapid growth within the epigenetics market. This expansion is driven by the increasing global footprint of local companies through strategic alliances and collaborations, alongside continuous enhancements in healthcare infrastructure in emerging economies. Moreover, there is a heightened emphasis on advancing capabilities in Next-Generation Sequencing (NGS), which is further propelling market development in the region. Request Sample Pages : Key players in the epigenetics market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher (US), Active Motif, Inc. (US), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Revvity (US), QIAGEN (Germany), among others. Illumina Inc (US): In 2024, Illumina, Inc. maintained a preeminent position in the genomics market, capitalizing on a well-established customer base that includes leading pharmaceutical and biotechnology companies, genomic research institutions, and various government laboratories and hospitals. The firm possesses a dominant market share in the next-generation sequencing (NGS) domain, which affords it a competitive edge when exploring adjacent sectors, such as epigenetic sequencing. A notable move in this direction occurred in June 2025, when Illumina announced its acquisition of SomaLogic. This strategic acquisition is poised to bolster Illumina's footprint in the burgeoning epigenetics market and further its multiomics strategy, integrating diverse biological data for enhanced insights into genomics, transcriptomics, proteomics, and epigenomics. Thermofisher Scientific Inc. (US) Thermo Fisher Scientific Inc. (US) stands out as a prominent player in the epigenetics market in 2024, driven by a robust and diversified product portfolio, an extensive global footprint, and a strategic focus on both organic and inorganic growth initiatives. Notably, in July 2025, the company secured US Food and Drug Administration (FDA) approval for the Oncomine Dx Express Test, utilizing the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay designed for companion diagnostics (CDx) in tumor profiling applications. Thermo Fisher demonstrates a strong commitment to research and development, channeling significant resources into innovation to address the dynamic needs of its clientele. Their comprehensive global distribution network enhances accessibility and customer support, facilitating the delivery of advanced and reliable epigenetics solutions. This multifaceted strategic approach solidifies Thermo Fisher's position as a leading provider in the epigenetics landscape. For more information, Inquire Now! Related Reports: Research Antibodies & Reagents Market Genomics Market Next Generation Sequencing Market PCR Technologies Market Digital PCR and qPCR Market Get access to the latest updates on Epigenetics Companies and Epigenetics Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$21.72 billion by the end of the period. The rise of the electrophysiology market can be attributed to several drivers: the increasing prevalence of cardiovascular diseases, including arrhythmias and atrial fibrillation; patients and healthcare providers are increasingly favoring minimally invasive procedures over traditional surgical interventions; electrophysiological techniques, such as catheter ablation, offer less invasive options for treating certain cardiac arrhythmias; and government support and initiatives aimed at improving healthcare infrastructure and funding research and development in electrophysiology also contribute to market growth. Download PDF Brochure: Browse in-depth TOC on "Electrophysiology Market" 322 - Tables62 - Figures330 - Pages By product, in 2024, electrophysiology ablation catheters are expected to be the leading segment in the medical device market. This anticipated growth is largely driven by the rising global prevalence of atrial fibrillation (AF) and various cardiac arrhythmias, which has increased the demand for minimally invasive ablation techniques. Recent technological advancements in catheter design, such as the introduction of contact force-sensing mechanisms, irrigated-tip designs, and high-power short-duration (HPSD) ablation systems, have greatly enhanced procedural safety, precision, and clinical outcomes. These innovations are contributing to wider acceptance and increased utilization of these catheters within the medical community. By indication, the electrophysiology market, divided by medical indications, includes segments such as atrial fibrillation, atrial flutter, and atrioventricular nodal reentry tachycardia. Atrial flutter, characterized by rapid heartbeats from the atria, is increasingly common, especially among the elderly, due to age-related cardiac changes. This rising prevalence has created a demand for advanced diagnosis and treatment options tailored to atrial flutter. Innovations in catheter ablation, advanced imaging techniques, and new pharmacological therapies reflect the urgency for effective arrhythmia management in an aging population. By geography, in 2024, North America, primarily the US and Canada, is set for significant growth in the medical technology market. The region is a global leader in medical innovations, especially in electrophysiology, often adopting breakthroughs ahead of others. With some of the highest healthcare spending globally, the US influences the uptake of advanced medical technologies, enhancing patient outcomes and operational efficiency. Strong A investment in research and development fosters innovation and creates a robust marketplace for new products and services, solidifying North America's role as a key driver of growth in the medical technology sector. Request Sample Pages : As of 2024, prominent players in the electrophysiology market are Johnson & Johnson Services, Inc. (US), Abbott (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Boston Scientific Corporation (US), Japan Lifeline Co., Ltd (Japan), Stereotaxis, Inc. (US), MicroPort Scientific Corporation (China), and BIOTRONIK (Germany). Abbott (US): Abbott Laboratories is a comprehensive healthcare company that operates across diverse sectors, including pharmaceuticals, medical devices, diagnostics, and nutrition. The company has established a significant presence in electrophysiology, particularly in the development of advanced medical devices for cardiac electrophysiology procedures. Abbott's portfolio in this specialized market includes sophisticated mapping systems, electrophysiology catheters, and related technologies designed for the precise diagnosis and management of cardiac arrhythmias. Furthermore, Abbott is likely engaged in ongoing research and development initiatives aimed at innovating and enhancing electrophysiological technologies to improve patient outcomes and procedural efficiencies. Koninklijke Philips N.V. (Netherlands) Koninklijke Philips N.V. Philips, a Netherlands-based multinational company, is a significant player in the healthcare sector, particularly within medical technology. The company develops an extensive range of products that enhance capabilities in cardiology, patient monitoring, diagnostic imaging, and electrophysiology. In the electrophysiology domain, Philips offers advanced solutions aimed at the identification and management of cardiac arrhythmias. This product suite includes high-precision imaging technologies, advanced mapping systems, and specialized electrophysiology catheters, all essential tools utilized by cardiology professionals. Key offerings include the EP WorkMate system, which serves as a comprehensive electrophysiology recording and reporting platform, facilitating efficient data capture and analysis during procedures. Additionally, Philips has introduced state-of-the-art X-ray imaging systems designed for enhanced visualization during electrophysiological interventions. The EP Navigator and EP-XT Mapping system are also part of their innovative portfolio, providing clinicians with advanced three-dimensional mapping capabilities that improve procedural accuracy and patient outcomes. For more information, Inquire Now! Related Reports: Defibrillator Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Ablation Technology Market Catheters Market Digital X-ray Market Get access to the latest updates on Electrophysiology Companies and Electrophysiology Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets
